Physician profile
Kelly Colas
NPI 1831659085
$13,787.06
in general payments reported to CMS, 2019-2025
13 companies · $8,412 in 2025
The $8,412 reported for 2025 was more than what 89% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.94 · 2022: $342 · 2023: $797 · 2024: $4,218 · 2025: $8,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,955.65 |
| Food and Beverage | $1,471.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,955.65 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $373.99 | 2023-2025 | Orladeyo |
| Blueprint Medicines Corporation | $272.77 | 2022-2024 | Ayvakit |
| Genzyme Corporation | $270.48 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $245.76 | 2022-2024 | Fasenra, Airsupra |
| Genentech, INC. | $175.72 | 2023 | Xolair |
| Adma Biomanufacturing LLC | $150.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.96 | 2022-2024 | Cuvitru |
| Csl Behring | $85.65 | 2023 | Hizentra |
| Amgen INC. | $61.55 | 2023 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $38.66 | 2024 | Dupixent |
| Smith+Nephew, INC. | $17.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.93 | 2023 | Spiriva Respimat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Colas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.